Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk

SIMPLE SUMMARY: Since B cells have been linked to multiple sclerosis (MS) and its progression as well as T cells, the second-generation anti-CD20 recombinant humanized monoclonal antibody ocrelizumab has been approved for MS treatment. Although ocrelizumab efficiently depletes B cells in peripheral...

Descripción completa

Detalles Bibliográficos
Autores principales: Zingaropoli, Maria Antonella, Pasculli, Patrizia, Tartaglia, Matteo, Dominelli, Federica, Ciccone, Federica, Taglietti, Ambra, Perri, Valentina, Malimpensa, Leonardo, Ferrazzano, Gina, Iannetta, Marco, Del Borgo, Cosmo, Lichtner, Miriam, Mastroianni, Claudio Maria, Conte, Antonella, Ciardi, Maria Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135639/
https://www.ncbi.nlm.nih.gov/pubmed/37106787
http://dx.doi.org/10.3390/biology12040587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135639/
https://www.ncbi.nlm.nih.gov/pubmed/37106787
http://dx.doi.org/10.3390/biology12040587

Ejemplares similares